Nexentis Technologies Slides on Private Offerings

Dow Jones

Jun 23

By Dean Seal

Shares of Nexentis Technologies sank after the company said it would sell shares to certain investors at about $7 apiece, below Monday's closing price.

The stock dropped 44%, to $6.90, after hours, giving back much of the surge it got during the trading day that saw it close at $13. It finished trading last week at $5.08.

Investors rallied behind the stock after Nexentis said on Monday morning that its subsidiary was working with artificial-intelligence research lab Boltz to accelerate the discovery of new cancer-fighting small-molecule drug candidates.

After the closing bell, Nexentis said it agreed to issue and sell nearly 411,000 shares to certain investors in a direct offering at a price of just under $7.06 a share. It has also agreed to issue those investors another roughly 411,000 warrants, each of which can be exercised to buy a share at just under $7.06.

The company expects to receive about $2.9 million in gross proceeds from the offerings, which is set to close on Wednesday.

Nexentis currently only has about 1 million shares outstanding, according to FactSet.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 22, 2026 17:41 ET (21:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2645008246"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645008246\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645008246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645008246","market":"sg","top_or_hot":-1,"title":"Nexentis Technologies Slides on Private Offerings","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Nexentis Technologies sank after the company said it would sell shares to certain investors at about $7 apiece, below Monday's closing price. \n</p>\n<p>\n  The stock dropped 44%, to $6.90, after hours, giving back much of the surge it got during the trading day that saw it close at $13. It finished trading last week at $5.08. \n</p>\n<p>\n  Investors rallied behind the stock after Nexentis said on Monday morning that its subsidiary was working with artificial-intelligence research lab Boltz to accelerate the discovery of new cancer-fighting small-molecule drug candidates. \n</p>\n<p>\n  After the closing bell, Nexentis said it agreed to issue and sell nearly 411,000 shares to certain investors in a direct offering at a price of just under $7.06 a share. It has also agreed to issue those investors another roughly 411,000 warrants, each of which can be exercised to buy a share at just under $7.06. \n</p>\n<p>\n  The company expects to receive about $2.9 million in gross proceeds from the offerings, which is set to close on Wednesday. \n</p>\n<p>\n  Nexentis currently only has about 1 million shares outstanding, according to FactSet. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 17:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexentis Technologies Slides on Private Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexentis Technologies Slides on Private Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-23 05:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Nexentis Technologies sank after the company said it would sell shares to certain investors at about $7 apiece, below Monday's closing price. \n</p>\n<p>\n  The stock dropped 44%, to $6.90, after hours, giving back much of the surge it got during the trading day that saw it close at $13. It finished trading last week at $5.08. \n</p>\n<p>\n  Investors rallied behind the stock after Nexentis said on Monday morning that its subsidiary was working with artificial-intelligence research lab Boltz to accelerate the discovery of new cancer-fighting small-molecule drug candidates. \n</p>\n<p>\n  After the closing bell, Nexentis said it agreed to issue and sell nearly 411,000 shares to certain investors in a direct offering at a price of just under $7.06 a share. It has also agreed to issue those investors another roughly 411,000 warrants, each of which can be exercised to buy a share at just under $7.06. \n</p>\n<p>\n  The company expects to receive about $2.9 million in gross proceeds from the offerings, which is set to close on Wednesday. \n</p>\n<p>\n  Nexentis currently only has about 1 million shares outstanding, according to FactSet. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 17:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4093","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645008246","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645008246","pubTimestamp":1782164460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Nexentis Technologies sank after the company said it would sell shares to certain investors at about $7 apiece, below Monday's closing price.The stock dropped 44%, to $6.90, after hours, giving back much of the surge it got during the trading day that saw it close at $13. It finished trading last week at $5.08.Investors rallied behind the stock after Nexentis said on Monday morning that its subsidiary was working with artificial-intelligence research lab Boltz to accelerate the discovery of new cancer-fighting small-molecule drug candidates.After the closing bell, Nexentis said it agreed to issue and sell nearly 411,000 shares to certain investors in a direct offering at a price of just under $7.06 a share. It has also agreed to issue those investors another roughly 411,000 warrants, each of which can be exercised to buy a share at just under $7.06.The company expects to receive about $2.9 million in gross proceeds from the offerings, which is set to close on Wednesday.Nexent","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4093":"化肥与农用药剂","NXTS":"Nexentis Technologies Inc"},"translate_title":"Nexentis Technologies私募发行下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXTS":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Nexentis Technologies sank after the company said it would sell shares to certain investors at about $7 apiece, below Monday's closing price. \n\n\n  The stock dropped 44%, to $6.90, after hours, giving back much of the surge it got during the trading day that saw it close at $13. It finished trading last week at $5.08. \n\n\n  Investors rallied behind the stock after Nexentis said on Monday morning that its subsidiary was working with artificial-intelligence research lab Boltz to accelerate the discovery of new cancer-fighting small-molecule drug candidates. \n\n\n  After the closing bell, Nexentis said it agreed to issue and sell nearly 411,000 shares to certain investors in a direct offering at a price of just under $7.06 a share. It has also agreed to issue those investors another roughly 411,000 warrants, each of which can be exercised to buy a share at just under $7.06. \n\n\n  The company expects to receive about $2.9 million in gross proceeds from the offerings, which is set to close on Wednesday. \n\n\n  Nexentis currently only has about 1 million shares outstanding, according to FactSet. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 17:41 ET (21:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}